AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Holdings Lifted by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. lifted its holdings in AbCellera Biologics Inc. (NASDAQ:ABCL) by 85.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 19,500 shares of the company’s stock after buying an additional 9,000 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in AbCellera Biologics were worth $111,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Pacifica Partners Inc. lifted its position in shares of AbCellera Biologics by 82.9% in the 4th quarter. Pacifica Partners Inc. now owns 4,820 shares of the company’s stock worth $28,000 after buying an additional 2,185 shares during the last quarter. Signaturefd LLC lifted its position in shares of AbCellera Biologics by 306.3% in the 4th quarter. Signaturefd LLC now owns 10,596 shares of the company’s stock worth $61,000 after buying an additional 7,988 shares during the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in shares of AbCellera Biologics in the 4th quarter worth about $62,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of AbCellera Biologics in the 4th quarter worth about $81,000. Finally, Janney Montgomery Scott LLC bought a new position in shares of AbCellera Biologics in the 3rd quarter worth about $88,000. 61.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, KeyCorp cut their price objective on shares of AbCellera Biologics from $8.00 to $7.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 8th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, AbCellera Biologics currently has a consensus rating of “Buy” and a consensus price target of $16.17.

AbCellera Biologics Trading Up 2.8 %

AbCellera Biologics stock opened at $2.96 on Friday. The stock has a market cap of $870.39 million, a price-to-earnings ratio of -5.69 and a beta of 0.45. The company’s 50-day moving average price is $3.62 and its two-hundred day moving average price is $4.55. AbCellera Biologics Inc. has a 52 week low of $2.71 and a 52 week high of $8.05.

AbCellera Biologics (NASDAQ:ABCL) last released its earnings results on Tuesday, May 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. The firm had revenue of $9.95 million for the quarter, compared to analysts’ expectations of $10.73 million. AbCellera Biologics had a negative net margin of 410.47% and a negative return on equity of 12.61%. AbCellera Biologics’s quarterly revenue was down 18.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.14) EPS. Research analysts expect that AbCellera Biologics Inc. will post -0.6 earnings per share for the current fiscal year.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.